Senti Biosciences to Present on Logic-Gated Cell Therapies in Educational Session at AACR Annual Meeting 2026
April 13, 2026 09:00 ET | Source: Senti Biosciences, Inc. SOUTH SAN…
Valitor Announces Oral Presentation at the Upcoming Association for Research in Vision and Ophthalmology (ARVO) 2026 Annual Meeting
April 07, 2026 08:00 ET | Source: Valitor, Inc. BERKELEY, Calif., April 07,…
Coway Holds 37th Annual General Meeting
Shareholders approve all board-proposed agenda itemsCumulative voting, electronic general meetings and the…
MoonLake announces Week 40 Results from its Phase 3 Clinical Trials of Sonelokimab in Hidradenitis Suppurativa at the 2026 AAD Annual Meeting
Results from the Phase 3 VELA clinical trials in adults with moderate-to-severe…
Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting
Poster #76954 highlights QTORIN™ rapamycin’s single phase anhydrous gel formulation designed to…
Annual General Meeting in cBrain A/S
Company Announcement no. 05/2026 Annual General Meeting 2026 Copenhagen, March 27, 2026…
Description of the share buyback program approved by the Ordinary General Shareholders’ Meeting of February 12, 2026
Pursuant to Article 241-2 of the General Regulations of the French Financial…
CORRECTING & REPLACING — MBX Biosciences Announces Successful End-of-Phase 2 FDA Meeting and Provides Phase 3 Development Plan for Once-Weekly Canvuparatide for Hypoparathyroidism
Following End-of-Phase 2 meeting, MBX remains on track to initiate Phase 3…
argenx to Present New Data at 2026 AAN Annual Meeting that Continue to Transform Patient Outcomes in MG and CIDP and Build Upon Strength of Pipeline
Positive results from Phase 3 ADAPT OCULUS study show VYVGART’s potential as…
DBV Technologies Highlights Additional Data from Successful Phase 3 VITESSE Study at the AAAAI 2026 Annual Meeting
Châtillon, France, February 28, 2026 DBV Technologies Highlights Additional Data from Successful…
